Anaconda Biomed Raises $56M Series B Led by Omega Funds for Stroke Thrombectomy Platform

Anaconda Biomed Secures $56M Series B

Anaconda Biomed, a Barcelona-based medical technology company, has raised $56 million in Series B funding. The round was led by Omega Funds, with participation from COFIDES FOCO, CDTI Innvierte, Asabys Partners, and Ysios Capital. The funding date is September 23, 2026.

What Anaconda Biomed Does

Anaconda Biomed develops next-generation thrombectomy catheters for the treatment of ischemic stroke. Its proprietary Funnel Catheter platform combines high-efficiency aspiration with flow arrest and flow reversal to improve clot capture, reduce embolic complications, and maximize brain reperfusion.

The company's portfolio spans the ANA5, ANA6, and ANA8 funnel catheters, as well as the Conda stent retriever. Anaconda Biomed operates its own production facility near Barcelona.

Clinical and Regulatory Progress

The company is completing the ATHENA pivotal IDE study to support clinical and regulatory requirements in global markets. This study is a key milestone for the company as it works toward broader market access.

Funding Details

• Round type: Series B
• Amount: $56,000,000
• Currency: USD
• Date: September 23, 2026
• Lead investor: Omega Funds
• Additional investors: COFIDES FOCO, CDTI Innvierte, Asabys Partners, Ysios Capital

Acquisition Perspective

The Series B round provides Anaconda Biomed with capital to advance its thrombectomy platform through the ATHENA pivotal IDE study and toward global regulatory submissions. For strategic acquirers in the neurovascular and medical device space, the company offers a differentiated catheter technology addressing ischemic stroke, a condition with significant unmet clinical need. The involvement of specialized life science investors such as Omega Funds, Asabys Partners, and Ysios Capital signals confidence in the platform's clinical and commercial potential. Anaconda Biomed's in-house production facility near Barcelona adds vertical integration that could be attractive to potential partners or acquirers seeking manufacturing capabilities in Europe.

As the company completes its pivotal study, it may become a target for larger medical device companies looking to expand their stroke intervention portfolios. The Series B funding positions Anaconda Biomed to execute on its clinical and regulatory strategy, making it a company to watch in the neurovascular space.